Johnson and Johnson applies for vaccine trials on adolescencents

23rd Aug, 2021

Johnson and Johnson applies for  vaccine trials on adolescencents

US Pharma company Johnson and Johnson has applied to the central drugs standard control organisation(CDSCO) seeking approval for the clinical trials of its single shot covid-19 vaccine on adolescencents of age 12 - 17 years in India.

Before this, in August emergency use approval(EUA) of Johnson and Johnson single dose covid-19 vaccine was approved in India ,and the health ministry said that it was in process to make the vaccine available for the general public as soon as possible.

Serum Institute's Covishield, Bharat Biotech's covaxine, Russia's sputnik V, moderna and now Johnson and Johnson are the five covid vaccines granted emergency use approval ,in India. Covid vaccine developed by Johnson and Johnson has proved to be 85% efficient in stopping serious covid-19 disease in its phase 3 trials.

J&J India spokesperson, said in a statement that to achieve the ultimate goal of herd immunity it is important that covid-19 vaccine clinical trials continue to proceed forward in this population ,and we are genuinely committed to the work required for the equitable distribution of the covid-19 vaccine for all age groups.